Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer

NCT00604721 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

NIH

Sponsor class

Conditions

Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions

DRUG: selumetinib
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)